Dr Abdou on Sequencing CDK4/6 Inhibitors in HER2– Metastatic Breast Cancer

Yara Abdou, MD, discusses findings from the phase 2 MAINTAIN trial in patients with HER2-negative metastatic breast cancer, as well as the clinical implications of these trial results.

Related Keywords

Yara Abdou , Department Of Medicine , University Of North Carolina School Medicine , Division Of Oncology , North Carolina School , D , Maintain Trial , Nct02632045 , Patients With Her2 Negative Metastatic Breast Cancer ,